CY1118461T1 - Φαρμακευτικες συνθεσεις που περιλαμβανουν αναστολεα αρωματασης - Google Patents
Φαρμακευτικες συνθεσεις που περιλαμβανουν αναστολεα αρωματασηςInfo
- Publication number
- CY1118461T1 CY1118461T1 CY20171100074T CY171100074T CY1118461T1 CY 1118461 T1 CY1118461 T1 CY 1118461T1 CY 20171100074 T CY20171100074 T CY 20171100074T CY 171100074 T CY171100074 T CY 171100074T CY 1118461 T1 CY1118461 T1 CY 1118461T1
- Authority
- CY
- Cyprus
- Prior art keywords
- pharmaceutical compositions
- aromatology
- ingredients
- compositions containing
- relates
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000004615 ingredient Substances 0.000 title 1
- 125000003626 1,2,4-triazol-1-yl group Chemical group [*]N1N=C([H])N=C1[H] 0.000 abstract 1
- 229940122815 Aromatase inhibitor Drugs 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000003886 aromatase inhibitor Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
- Nutrition Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Pregnancy & Childbirth (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161532459P | 2011-09-08 | 2011-09-08 | |
| US201261638588P | 2012-04-26 | 2012-04-26 | |
| PCT/US2012/053846 WO2013036563A1 (en) | 2011-09-08 | 2012-09-06 | Pharmaceutical compositions comprising an aromatase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1118461T1 true CY1118461T1 (el) | 2017-07-12 |
Family
ID=46846026
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171100074T CY1118461T1 (el) | 2011-09-08 | 2017-01-18 | Φαρμακευτικες συνθεσεις που περιλαμβανουν αναστολεα αρωματασης |
| CY20171100100T CY1118499T1 (el) | 2011-09-08 | 2017-01-24 | Χρηση ενος αναστολεα αρωματασης για την αντιμετωπιση υπογοναδισμου και σχετικων νοσων |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171100100T CY1118499T1 (el) | 2011-09-08 | 2017-01-24 | Χρηση ενος αναστολεα αρωματασης για την αντιμετωπιση υπογοναδισμου και σχετικων νοσων |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US9295668B2 (enExample) |
| EP (2) | EP2753313B1 (enExample) |
| JP (2) | JP6051467B2 (enExample) |
| KR (3) | KR20140071358A (enExample) |
| CN (2) | CN103796644B (enExample) |
| AR (1) | AR087790A1 (enExample) |
| AU (2) | AU2012304694B2 (enExample) |
| BR (2) | BR112014005434B1 (enExample) |
| CA (2) | CA2846884C (enExample) |
| CL (1) | CL2014000552A1 (enExample) |
| CY (2) | CY1118461T1 (enExample) |
| DK (2) | DK2753312T3 (enExample) |
| ES (2) | ES2613667T3 (enExample) |
| HR (2) | HRP20170003T1 (enExample) |
| HU (2) | HUE031478T2 (enExample) |
| IL (1) | IL231234A (enExample) |
| IN (1) | IN2014DN01619A (enExample) |
| LT (2) | LT2753312T (enExample) |
| MX (2) | MX343902B (enExample) |
| PE (1) | PE20141584A1 (enExample) |
| PH (1) | PH12014500435A1 (enExample) |
| PL (2) | PL2753313T3 (enExample) |
| PT (2) | PT2753313T (enExample) |
| RU (2) | RU2617510C2 (enExample) |
| SG (2) | SG2014012132A (enExample) |
| SI (2) | SI2753312T1 (enExample) |
| TN (1) | TN2014000059A1 (enExample) |
| TW (1) | TW201316987A (enExample) |
| UY (1) | UY34315A (enExample) |
| WO (2) | WO2013036562A1 (enExample) |
| ZA (1) | ZA201401040B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2753312T1 (sl) * | 2011-09-08 | 2017-10-30 | Mereo Biopharma 2 Limited | Uporaba inhibitorja aromataze za zdravljenje hipogonadizma in sororodnih bolezni |
| WO2015148549A1 (en) * | 2014-03-26 | 2015-10-01 | The Regents Of The University Of California | Ultrasensitive androgen receptor bioassay |
| PT3166596T (pt) * | 2014-07-07 | 2018-10-19 | Novartis Ag | Formas farmacêuticas |
| GB201614179D0 (en) * | 2016-08-19 | 2016-10-05 | Mereo Biopharma 2 Ltd | Dosage regimen for the treatment of endometriosis |
| JP2020510027A (ja) * | 2017-03-08 | 2020-04-02 | アリアド ファーマシューティカルズ，インコーポレーテッド | ５−クロロ−ｎ４−［２−（ジメチルホスホリル）フェニル］−ｎ２−｛２−メトキシ−４−［４−（４−メチルピペラジン−１−イル）ピペリジン−１−イル］フェニル｝ピリミジン−２，４−ジアミンを含む医薬製剤 |
| CA3078652A1 (en) | 2017-10-12 | 2019-04-18 | Novo Nordisk A/S | Semaglutide in medical therapy |
| USD894149S1 (en) * | 2018-08-16 | 2020-08-25 | Alibaba Group Holding Limited | Information terminal for payment |
| USD894148S1 (en) * | 2018-08-16 | 2020-08-25 | Alibaba Group Holding Limited | Information terminal for payment |
| JP7121999B2 (ja) * | 2019-09-26 | 2022-08-19 | 学校法人九州文化学園 | 男性性腺機能低下症治療剤 |
| US12552754B1 (en) | 2025-06-11 | 2026-02-17 | ReproNovo SA | Leflutrozole compositions of matter and processes for preparation |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4749713A (en) | 1986-03-07 | 1988-06-07 | Ciba-Geigy Corporation | Alpha-heterocycle substituted tolunitriles |
| TW210334B (enExample) * | 1990-12-12 | 1993-08-01 | Ciba Geigy Ag | |
| DE4435368A1 (de) * | 1994-09-22 | 1996-03-28 | Schering Ag | Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann |
| US5972921A (en) * | 1997-12-12 | 1999-10-26 | Hormos Medical Oy Ltd. | Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men |
| AU2001271162A1 (en) * | 2000-07-05 | 2002-01-14 | Astrazeneca Ab | Pharmaceutical combination of an anti-androgen and letrozole for providing an anit-androgenic effect and aromatase inhibition |
| SK14252003A3 (sk) | 2001-04-17 | 2004-03-02 | Ares Trading S. A. | Použitie aromatázového inhibítora, farmaceutický prostriedok s obsahom aromatázového inhibítora a farmaceutické balenie |
| US7101573B2 (en) * | 2001-09-28 | 2006-09-05 | Mcneil-Pcc, Inc. | Simethicone solid oral dosage form |
| AU2003213957A1 (en) | 2002-04-03 | 2003-10-13 | Jencap Research Ltd. | Pharmaceutical composition comprising an aromatase inhibitor and an estrogen suitable for hormone replacement therapy for a male |
| WO2006114702A2 (en) | 2005-04-25 | 2006-11-02 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor |
| CN102335219A (zh) * | 2007-11-21 | 2012-02-01 | 客乐谐制药株式会社 | 芳香酶抑制剂 |
| SI2753312T1 (sl) * | 2011-09-08 | 2017-10-30 | Mereo Biopharma 2 Limited | Uporaba inhibitorja aromataze za zdravljenje hipogonadizma in sororodnih bolezni |
-
2012
- 2012-09-06 SI SI201230850T patent/SI2753312T1/sl unknown
- 2012-09-06 PL PL12758966T patent/PL2753313T3/pl unknown
- 2012-09-06 PT PT127589661T patent/PT2753313T/pt unknown
- 2012-09-06 RU RU2014113575A patent/RU2617510C2/ru active
- 2012-09-06 BR BR112014005434-7A patent/BR112014005434B1/pt active IP Right Grant
- 2012-09-06 ES ES12758966.1T patent/ES2613667T3/es active Active
- 2012-09-06 AR ARP120103283A patent/AR087790A1/es unknown
- 2012-09-06 HU HUE12758965A patent/HUE031478T2/hu unknown
- 2012-09-06 RU RU2014113334A patent/RU2628808C2/ru active
- 2012-09-06 EP EP12758966.1A patent/EP2753313B1/en active Active
- 2012-09-06 KR KR1020147006170A patent/KR20140071358A/ko not_active Ceased
- 2012-09-06 PT PT127589653T patent/PT2753312T/pt unknown
- 2012-09-06 AU AU2012304694A patent/AU2012304694B2/en active Active
- 2012-09-06 JP JP2014529833A patent/JP6051467B2/ja active Active
- 2012-09-06 CA CA2846884A patent/CA2846884C/en active Active
- 2012-09-06 MX MX2014002773A patent/MX343902B/es active IP Right Grant
- 2012-09-06 CN CN201280043378.9A patent/CN103796644B/zh active Active
- 2012-09-06 SG SG2014012132A patent/SG2014012132A/en unknown
- 2012-09-06 LT LTEP12758965.3T patent/LT2753312T/lt unknown
- 2012-09-06 IN IN1619DEN2014 patent/IN2014DN01619A/en unknown
- 2012-09-06 EP EP12758965.3A patent/EP2753312B1/en active Active
- 2012-09-06 KR KR1020187007058A patent/KR20180030254A/ko not_active Ceased
- 2012-09-06 DK DK12758965.3T patent/DK2753312T3/da active
- 2012-09-06 PL PL12758965T patent/PL2753312T3/pl unknown
- 2012-09-06 PE PE2014000325A patent/PE20141584A1/es not_active Application Discontinuation
- 2012-09-06 US US14/342,810 patent/US9295668B2/en active Active
- 2012-09-06 MX MX2014002780A patent/MX360315B/es active IP Right Grant
- 2012-09-06 HU HUE12758966A patent/HUE031435T2/en unknown
- 2012-09-06 US US14/342,813 patent/US9370505B2/en active Active
- 2012-09-06 LT LTEP12758966.1T patent/LT2753313T/lt unknown
- 2012-09-06 CN CN201280043614.7A patent/CN103781476B/zh active Active
- 2012-09-06 BR BR112014004879A patent/BR112014004879B1/pt active IP Right Grant
- 2012-09-06 KR KR1020147006171A patent/KR101872561B1/ko active Active
- 2012-09-06 SG SG10201607503WA patent/SG10201607503WA/en unknown
- 2012-09-06 CA CA2845929A patent/CA2845929C/en active Active
- 2012-09-06 WO PCT/US2012/053844 patent/WO2013036562A1/en not_active Ceased
- 2012-09-06 HR HRP20170003TT patent/HRP20170003T1/hr unknown
- 2012-09-06 PH PH1/2014/500435A patent/PH12014500435A1/en unknown
- 2012-09-06 JP JP2014529832A patent/JP6280501B2/ja active Active
- 2012-09-06 DK DK12758966.1T patent/DK2753313T3/en active
- 2012-09-06 HR HRP20170002TT patent/HRP20170002T1/hr unknown
- 2012-09-06 WO PCT/US2012/053846 patent/WO2013036563A1/en not_active Ceased
- 2012-09-06 ES ES12758965.3T patent/ES2613666T3/es active Active
- 2012-09-06 AU AU2012304693A patent/AU2012304693B2/en active Active
- 2012-09-06 SI SI201230848A patent/SI2753313T1/sl unknown
- 2012-09-07 TW TW101132840A patent/TW201316987A/zh unknown
- 2012-09-10 UY UY0001034315A patent/UY34315A/es not_active Application Discontinuation
-
2014
- 2014-02-10 TN TNP2014000059A patent/TN2014000059A1/en unknown
- 2014-02-11 ZA ZA2014/01040A patent/ZA201401040B/en unknown
- 2014-02-27 IL IL231234A patent/IL231234A/en active IP Right Grant
- 2014-03-07 CL CL2014000552A patent/CL2014000552A1/es unknown
-
2016
- 2016-02-22 US US15/050,394 patent/US9750724B2/en active Active
- 2016-05-27 US US15/167,867 patent/US10064844B2/en active Active
-
2017
- 2017-01-18 CY CY20171100074T patent/CY1118461T1/el unknown
- 2017-01-24 CY CY20171100100T patent/CY1118499T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX360315B (es) | Composiciones farmaceuticas que comprenden un inhibidor de aromatasa. | |
| CY1121373T1 (el) | Μεθοδος και φαρμακοτεχνικη μορφη για εισπνοη | |
| CY1119435T1 (el) | Σκευασμα για αντισωμα εναντι- αλφα4βητα7 | |
| TN2015000278A1 (en) | Autotaxin inhibitors | |
| EP2958913A4 (en) | SPHINGOSINE 1 PHOSPHATE RECEPTOR AGONISTS, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS THEREFOR AS ACTIVE AGENT | |
| PH12014502778A1 (en) | Antibody formulation | |
| GB2541835A (en) | Multivesicular liposome formulations of tranexamic acid | |
| EA201590805A1 (ru) | Композиция с немедленным и пролонгированным высвобождением | |
| MX2013008647A (es) | Metodo, composiciones y empaque para limpieza del intestino. | |
| TR200806298A2 (tr) | Farmasötik formülasyon | |
| MX391620B (es) | Formulaciones del inhibidor del antígeno-1 asociado a la función de linfocitos (lfa-1). | |
| MX2013013649A (es) | Compuestos de quinona para tratar enfermedades mediadas por ape1. | |
| MX2014014579A (es) | Composiciones farmaceuticas topicas de tipo emulsion aceite en agua que contienen un retinoide. | |
| WO2013104892A8 (en) | Application of high dose compounds via inhalation | |
| WO2013170086A3 (en) | Formulations for the delivery of active ingredients | |
| CL2012002893A1 (es) | Composición de al menos un ingrediente activo de origen vegetal o sintético análogo del mismo, o extracto de origen vegetal que lo contiene, en una solución acuosa, que además comprende lecitina como agente encapsulante; medicamento que la comprende; método para su preparación; y su uso para tratar parasitosis intestinales. | |
| CY1115600T1 (el) | Πιπεραζινες ως ανθελονοσιακοι παραγοντες | |
| TR200909785A1 (tr) | Aktif ajan olarak sefdinir içeren farmasötik kompozisyonlar. | |
| MY168692A (en) | The treatment of viral infections | |
| EA201491477A1 (ru) | Фармацевтические составы, содержащие флупиртин | |
| CL2012003685A1 (es) | Kit farmaceutico que comprende una o mas unidades de envasado que comprenden 21 a 28 unidades de dosificacion activas diarias en que cada una comprende por lo menos 2 mg de drosperidona, sin estrogernos; uso del kit y de una composicion farmaceutica que comprende drosperidona para preparar un medicamento util como anticonceptivo. | |
| CR11588A (es) | Formulaciones farmacéuticas semisólidas | |
| UA75916U (xx) | Медичний перев'язувальний виріб | |
| MX383685B (es) | Clonidina y/o derivados de clonidina para uso en la prevención de la lesión de la piel resultante de la radioterapia. | |
| TR201203084A2 (tr) | Sefditoren pivoksil ve klavulanik asit içeren formülasyonlar. |